Cell activation and apoptosis by bacterial lipoproteins through Toll- like receptor-2

Science

Volumn 285, Issue 5428, 1999, Pages 736-739

  Aliprantis, Antonios O ^a   Yang, Ruey Bing ^b   Mark, Melanie R ^b   Suggett, Shelly ^b   Devaux, Brigitte ^b   Radolf, Justin D ^c   Klimpel, Gary R ^d   Godowski, Paul ^b   Zychlinsky, Arturo ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN; MEMBRANE RECEPTOR;

APOPTOSIS; ARTICLE; CELL ACTIVATION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; APOPTOSIS; BACTERIAL PROTEINS; CELL LINE; CYCLOHEXIMIDE; CYTOTOXICITY, IMMUNOLOGIC; DROSOPHILA PROTEINS; GENES, REPORTER; HUMANS; LIPOPOLYSACCHARIDES; LIPOPROTEINS; MEMBRANE GLYCOPROTEINS; MONOCYTES; NF-KAPPA B; PROTEIN SYNTHESIS INHIBITORS; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

BACTERIA (MICROORGANISMS);

EID: 0033618630     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5428.736     Document Type: Article

References (35)

1. R. Medzhitov and C. A. Janeway Jr., Curr. Opin. Immunol. 9, 4 (1997).
2. B. Henderson, S. Poole, M. Wilson, Microbiol. Rev. 60, 316 (1996).
3. M. V. Norgard et al., Infect. Immun. 64, 3845 (1996).
4. M. Kreutz et al., Immunology 92, 396 (1997).
5. W. G. Bessler et al., J. Immunol. 135, 1900 (1985).
6. F. L. Rock, G. Hardiman, J. C. Timans, R. A. Kastelein, J. F. Bazan, Proc. Natl. Acad. Sci. U.S.A. 95, 588 (1998).
7. B. Lemaitre, E. Nicolas, L. Michaut, J. M. Reichhart, J. A. Hoffmann, Cell 86, 973 (1996); M. J. Williams, A. Rodriguez, D. A. Kimbrell, E. D. Eldon, EMBO J. 16, 6120 (1997).
8. B. Lemaitre, E. Nicolas, L. Michaut, J. M. Reichhart, J. A. Hoffmann, Cell 86, 973 (1996); M. J. Williams, A. Rodriguez, D. A. Kimbrell, E. D. Eldon, EMBO J. 16, 6120 (1997).
9. L. A. O'Neill and C. Greene, J. Leukocyte Biol. 63, 650 (1998).
10. R. B. Yang et al., Nature 395, 284 (1998).
11. C. J. Kirschning, H. Wesche, T. Merrill Ayres, M. Rothe, J. Exp. Med. 188, 2091 (1998).
12. A. Poltorak et al., Science 282, 2085 (1998).
13. H. Zhang, J. W. Peterson, D. W. Niesel, G. R. Klimpel, J. Immunol. 159, 4868 (1997).
14. R.-B. Yang, M. R. Mark, P. Godowski, unpublished data.
15. 3Cys was from Novabiochem. MLP (12) contained <25 pg of LP5 per milligram of protein. Unless indicated, other reagents were from Sigma.
16. P. Hoffmann et al., Immunobiology 177, 158 (1988).
17. Base treatment was done as in V. Vidal et al., Nature Med. 4, 1416 (1998). The products were resolved by reversed-phase high-performance liquid chromatography with a C4 column (Vydac) and a linear acetonitrile gradient. Fractions were analyzed by electrospray ionization mass spectrometry. A fraction was isolated that contained (i) a compound that has lost two of the three palmitate moieties (molecular weight = 1032.6, major peak) and (ii) a compound that has lost the entire S-[2,3-Bis(palmitoyloxy)-(2-RS)-propyl] moiety (molecular weight = 924.7, minor peak). The concentration was determined by ultraviolet absorption.
18. J. D. Radolf et al., J. Immunol. 154, 2866 (1995).
19. A. W. Segal and K. P. Shatwell, Ann. N.Y. Acad. Sci. 832, 215 (1997).
20. mAb 2392 was generated by immunization of BALB/c mice with the purified, extracellular domain of hTLR2 (9). The specificity of mAb 2392 for hTLR2 was confirmed by the following methods: (i) An enzyme-linked immunosorbent assay which demonstrated that mAb 2392 reacted with hTLR2-Fc but not hTLR4-Fc. (ii) A flow cytometric analysis with 293 cells expressing gD epitope-tagged versions of hTLR2, hTLR4, and hTLR6. Although each cell line was labeled with mAb 5B6, which recognizes the gD epitope, only 293hTLR2 cells were labeled with mAb 2392. (iii) An immunoprecipitation (24), followed by protein immunoblotting with mAb 5B6, from the membrane extracts of 293 cells transiently transfected with gD epitope-tagged versions of hTLR2, hTLR1, hTLR4, and murine TLR2. mAb 2392 only precipitated hTLR2. However, equivalent amounts of each receptor were obtained when mAb 5B6 was used for the immunoprecipitation. Supplemental data illustrating the specificity of mAb 2392 can be seen at www.sciencemag.org/feature/data/1040361. shl.
21. The test compounds were added to the 293 stable cell lines (9) in serum-free Dulbecco's modified Eagle's medium, 0.05% HSA, 5% fetal bovine serum (FBS). Cells were either photographed or stained with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) by using the Apoptosis Detection System (Promega) and analyzed by flow cytometry. At least 5000 events were counted per sample. Results are presented as specific apoptosis (%) determined as [(% TUNEL-positive cells in experimental - % TUNEL-positive cells in control)/(100 - % TUNEL-positive cells in control] × 100. The % TUNEL-positive cells in controls was always <5%.
22. J. Kerr, A. Wyllie, A. Currie, Br. J. Cancer 26, 239 (1972).
23. T. J. Sellati et al., J. Immunol. 160, 5455 (1998).
24. D. Heumann et al., ibid. 148, 3505 (1992).
25. A. O. Aliprantis and A. Zychlinsky, unpublished data.
26. Plasmids pKRN and phTLR2 (9) were prepared with the Endotoxin-free Plasmid Maxi kit (Qiagen). 293 cells were transfected with the Effectene Transfection reagent (Qiagen). Thirty hours after transfection, an equal volume of diluent or diluent containing sBLP (200 ng/ml) was added. Thirty-six hours later the cells were stained with Annexin V-biotin (Pharmingen) and Streptavidin Tri-Color (Caltag) and analyzed by flow cytometry.
27. THP-1 cells (American Type Culture Collection) were maintained in RPMI 1640, 10% FBS, penicillin, streptomycin, and 2 mM L-glutamine. Six hours after seeding THP-1 cells in RPMI 1640, the indicated compounds diluted in RPMI 1640, 0.05% HSA were added. Six hours later, cell death was quantified by a lactate dehydrogenase release assay (Promega). Where indicated, cells were first treated with 32 nM PMA for 6 hours or cotreated with cycloheximide (50 μg/ml). PMA and cytcoheximide diluents (dimethyl sulfoxide and ethanol) were not cytotoxic.
28. H. D. Brightbill et al., Science 285, 732 (1999).
29. A. Ashkenazi and V. M. Dixit, ibid. 281, 1305 (1998).
30. J. E. Moss, A. O. Aliprantis, A. Zychlinsky, Int. Rev. Cytol. 187, 203 (1999).
31. A. Zychlinsky and P. Sansonetti, J. Clin. Invest. 100, 493 (1997).
32. J. Savill, J. Leukocyte Biol. 61, 375 (1997).
33. W. G. Bessler et al., Int. J. Immunopharmacol. 19, 547 (1997).
34. N. M. Iovine, P. Elsbach, J. Weiss, Proc. Natl. Acad. Sci. U.S.A. 94, 10973 (1997).
35. We thank D. Littman, V. Dixit, C. Scharff, and J. Moss for critical reading of the manuscript, M. Garabedlan for discussions, and T. Neubert for mass spectrometry analysis. pCDNA3 and pGFP were a gift of the Littman Lab. A.O.A. was supported by a grant from the Ufe and Health Insurance Fund. This work was supported by grants from the National Institute of Allergy and Infectious Diseases (AI 37720-04 to A.Z. and AI-38394 to J.D.R.).